TY - JOUR
T1 - Development of plant-made monoclonal antibodies against viral infections
AU - Chen, Qiang
N1 - Funding Information:
The authors thank Josh Lesio for the critical reading of the manuscript. Relevant research in the author’s laboratory was supported in part by the US National Institute of Allergy and Infectious Diseases (NIAID) grants U01 AI075549 and R21/R33AI101329 to Qiang Chen.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2022/2
Y1 - 2022/2
N2 - Current plant-based systems offer multiple advantages for monoclonal antibody (mAb) development and production beyond the traditional benefits of low cost and high scalability. Novel expression vectors have allowed the production of mAbs at high levels with unprecedented speed to combat current and future pandemics. Host glycoengineering has enabled plants to produce mAbs that have unique mammalian glycoforms with a high degree of homogeneity. These mAb glycovariants exhibit differential binding to various Fc receptors, providing a new way to optimize antibody effector function for improving mAb potency or safety. This review will summarize the status of anti-viral mAb development with plant-based systems. The preclinical and clinical development of leading plant-made mAb candidates will be highlighted. In addition, the remaining challenges and potential applications of this technology will be discussed.
AB - Current plant-based systems offer multiple advantages for monoclonal antibody (mAb) development and production beyond the traditional benefits of low cost and high scalability. Novel expression vectors have allowed the production of mAbs at high levels with unprecedented speed to combat current and future pandemics. Host glycoengineering has enabled plants to produce mAbs that have unique mammalian glycoforms with a high degree of homogeneity. These mAb glycovariants exhibit differential binding to various Fc receptors, providing a new way to optimize antibody effector function for improving mAb potency or safety. This review will summarize the status of anti-viral mAb development with plant-based systems. The preclinical and clinical development of leading plant-made mAb candidates will be highlighted. In addition, the remaining challenges and potential applications of this technology will be discussed.
UR - http://www.scopus.com/inward/record.url?scp=85121328587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121328587&partnerID=8YFLogxK
U2 - 10.1016/j.coviro.2021.12.005
DO - 10.1016/j.coviro.2021.12.005
M3 - Review article
C2 - 34933212
AN - SCOPUS:85121328587
SN - 1879-6257
VL - 52
SP - 148
EP - 160
JO - Current Opinion in Virology
JF - Current Opinion in Virology
ER -